Emergent Biosolutions Inc.

3.26-0.1800-5.23%Vol 1.50M1Y Perf -83.73%
Sep 22nd, 2023 16:00 DELAYED
BID3.21 ASK3.27
Open3.44 Previous Close3.44
Pre-Market- After-Market3.24
 - -  -0.02 -0.61%
Target Price
36.50 
Analyst Rating
Hold 3.00
Potential %
1.02K 
Finscreener Ranking
★★★+     50.57
Insiders Trans % 3/6/12 mo.
-100/-100/-33 
Value Ranking
★★★+     54.40
Insiders Value % 3/6/12 mo.
-100/-100/2 
Growth Ranking
★★★★     57.52
Insiders Shares Cnt. % 3/6/12 mo.
-100/-100/-3 
Income Ranking
 —    -
Price Range Ratio 52W %
-0.74 
Earnings Rating
Strong Sell
Market Cap168.89M 
Earnings Date
14th Nov 2023
Alpha-0.04 Standard Deviation0.15
Beta0.88 

Today's Price Range

3.203.47

52W Range

3.4022.35

5 Year PE Ratio Range

5.30133.60

Summary:

Sell

Technical Indicators: Neutral
Moving Averages: Strong Sell
Performance
1 Week
-17.88%
1 Month
-28.04%
3 Months
-65.02%
6 Months
-58.52%
1 Year
-83.73%
3 Years
-96.81%
5 Years
-95.06%
10 Years
-83.22%

TickerPriceChg.Chg.%
EBS3.26-0.1800-5.23
AAPL174.790.86000.49
GOOG131.25-0.1100-0.08
MSFT317.01-2.5200-0.79
XOM114.940.18000.16
WFC41.23-1.0900-2.58
JNJ160.50-1.1600-0.72
FB196.640.99000.51
GE111.25-1.7400-1.54
JPM145.73-1.4100-0.96
Financial StrengthValueIndustryS&P 500US Markets
1.60
4.20
0.42
0.73
4.50
Leverage Ratio 1.90
ProfitabilityValueIndustryS&P 500US Markets
58.10
9.90
19.00
20.30
-17.19
RevenueValueIndustryS&P 500US Markets
790.20M
15.84
25.09
30.25
Earnings HistoryEstimateReportedSurprise %
Q02 2023-0.98-1.06-8.16
Q01 2023-1.67-3.17-89.82
Q04 20220.32-0.31-196.88
Q03 2022-0.06-1.27-2 016.67
Q02 20220.63-0.86-236.51
Q01 20220.240.18-25.00
Q04 20213.894.5015.68
Q03 20212.03-0.36-117.73
Earnings Per EndEstimateRevision %Trend
9/2023 QR0.05-91.53Negative
12/2023 QR0.94-52.76Negative
12/2023 FY-3.24-117.45Negative
12/2024 FY2.10940.00Positive
Next Report Date14th Nov 2023
Estimated EPS Next Report0.05
Estimates Count1
EPS Growth Next 5 Years %-
Volume Overview
Volume1.50M
Shares Outstanding51.81K
Shares Float46.63M
Trades Count7.88K
Dollar Volume4.88M
Avg. Volume3.31M
Avg. Weekly Volume4.07M
Avg. Monthly Volume3.60M
Avg. Quarterly Volume2.24M

Emergent Biosolutions Inc. (NYSE: EBS) stock closed at 3.26 per share at the end of the most recent trading day (a -5.23% change compared to the prior day closing price) with a volume of 1.50M shares and market capitalization of 168.89M. Is a component of indices and it is traded on NYSE exchange. The company belongs in the Drug Manufacturers industry, Healthcare sector and employs 2200 people. Emergent Biosolutions Inc. CEO is Robert G. Kramer.

The one-year performance of Emergent Biosolutions Inc. stock is -83.73%, while year-to-date (YTD) performance is -72.4%. EBS stock has a five-year performance of -95.06%. Its 52-week range is between 3.4 and 22.35, which gives EBS stock a 52-week price range ratio of -0.74%

Emergent Biosolutions Inc. currently has a PE ratio of 17.40, a price-to-book (PB) ratio of 0.47, a price-to-sale (PS) ratio of 0.83, a price to cashflow ratio of 3.40, a PEG ratio of 2.85, a ROA of 2.00%, a ROC of 3.02% and a ROE of 3.91%. The company’s profit margin is -17.19%, its EBITDA margin is 19.00%, and its revenue ttm is $790.20 Million , which makes it $15.84 revenue per share.

Of the last four earnings reports from Emergent Biosolutions Inc., there were 0 positive earnings surprise and 4 negative earnings surprise. The company has EPS estimate of $0.05 for the next earnings report. Emergent Biosolutions Inc.’s next earnings report date is 14th Nov 2023.

The consensus rating of Wall Street analysts for Emergent Biosolutions Inc. is Hold (3), with a target price of $36.5, which is +1 019.63% compared to the current price. The earnings rating for Emergent Biosolutions Inc. stock is Strong Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Emergent Biosolutions Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Emergent Biosolutions Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 17.43, ATR14 : 0.38, CCI20 : -158.84, Chaikin Money Flow : -0.25, MACD : -0.56, Money Flow Index : 13.51, ROC : -28.82, RSI : 26.96, STOCH (14,3) : 2.99, STOCH RSI : 0.00, UO : 35.44, Williams %R : -97.01), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Emergent Biosolutions Inc. in the last 12-months were: Ronald B. Richard (Sold 1 912 shares of value $22 829 ), Zoon Kathryn C (Sold 3 530 shares of value $29 526 )

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
0 (0.00 %)
1 (50.00 %)
1 (33.33 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
2 (100.00 %)
1 (50.00 %)
2 (66.67 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingHold
3.00
Moderate Buy
2.00
Moderate Buy
2.33

Emergent Biosolutions Inc.

Emergent BioSolutions offers public health products to government and healthcare providers. The company has four main units: vaccines, which produces specialty vaccines for public health threats; devices, such as nasal sprays, skin lotions, and injections; therapeutics, which includes antibody-based treatments; and contract development and manufacturing, which brings treatments to market through collaboration with the pharmaceutical and biotechnology industries and the United States government. Most revenue comes from U.S. government purchases of vaccine, device, and therapeutic products.

CEO: Robert G. Kramer

Telephone: +1 240 631-3200

Address: 400 Professional Drive, Gaithersburg 21079, MD, US

Number of employees: 2 200

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

56%44%

Bearish Bullish

57%43%

Bearish Bullish

58%42%

 

News

Stocktwits